Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CD1D Biologics Sequence Review Report 2026: Antigen-presenting glycoprotein CD1d Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD1D Biologics Sequence Review Report 2026: Antigen-presenting glycoprotein CD1d Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD1D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD1C Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD1c Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD1C Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD1c Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD1C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD1B Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD1b Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD1B Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD1b Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD177 Biologics Sequence Review Report 2026: CD177 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD177 Biologics Sequence Review Report 2026: CD177 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD177 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD151 Biologics Sequence Review Report 2026: CD151 antigen Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD151 Biologics Sequence Review Report 2026: CD151 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD151 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD14 Biologics Sequence Review Report 2026: Monocyte differentiation antigen CD14 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD14 Biologics Sequence Review Report 2026: Monocyte differentiation antigen CD14 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL28 Biologics Sequence Review Report 2026: C-C motif chemokine 28 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL28 Biologics Sequence Review Report 2026: C-C motif chemokine 28 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCL28 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL27 Biologics Sequence Review Report 2026: C-C motif chemokine 27 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL27 Biologics Sequence Review Report 2026: C-C motif chemokine 27 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCL27 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL23 Biologics Sequence Review Report 2026: C-C motif chemokine 23 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL23 Biologics Sequence Review Report 2026: C-C motif chemokine 23 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCL23 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL15 Biologics Sequence Review Report 2026: C-C motif chemokine 15 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL15 Biologics Sequence Review Report 2026: C-C motif chemokine 15 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCL15 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TGFBRAP1 Biologics Sequence Review Report 2026: Transforming growth factor-beta receptor-associated protein 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TGFBRAP1 Biologics Sequence Review Report 2026: Transforming growth factor-beta receptor-associated protein 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TGFBRAP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TGFBR3 Biologics Sequence Review Report 2026: Transforming growth factor beta receptor type 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TGFBR3 Biologics Sequence Review Report 2026: Transforming growth factor beta receptor type 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TGFBR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →